UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 176

Sortiert nach

How Can Vaccines Contribute to Solving the Antimicrobial Resistance Problem?

mBio, 2016-06, Vol.7 (3)

2016

Volltextzugriff (PDF)

Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies

Vaccine, 2007-05, Vol.25 (19), p.3816-3826

2007

Volltextzugriff (PDF)

Which Pneumococcal Serogroups Cause the Most Invasive Disease: Implications for Conjugate Vaccine Formulation and Use, Part I

Clinical infectious diseases, 2000-01, Vol.30 (1), p.100-121

2000

Volltextzugriff (PDF)

Serum Serotype-Specific Pneumococcal Anticapsular Immunoglobulin G Concentrations after Immunization with a 9-Valent Conjugate Pneumococcal Vaccine Correlate with Nasopharyngeal Acquisition of Pneumococcus

The Journal of infectious diseases, 2005-08, Vol.192 (3), p.367-376

2005

Volltextzugriff (PDF)

SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines

Human vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2301632-2301632

2024

Volltextzugriff (PDF)

Efficacy of a Pneumococcal Conjugate Vaccine against Acute Otitis Media

The New England journal of medicine, 2001-02, Vol.344 (6), p.403-409

2001

Volltextzugriff (PDF)

Identification of novel virus-specific antigens by CD4+ and CD8+ T cells from asymptomatic HSV-2 seropositive and seronegative donors

Virology (New York, N.Y.), 2014-09, Vol.464, p.296-311

2014

Volltextzugriff (PDF)

Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants

Vaccine, 2003-07, Vol.21 (23), p.3265-3272

2003

Volltextzugriff (PDF)

The Contribution of Specific Pneumococcal Serogroups to Different Disease Manifestations: Implications for Conjugate Vaccine Formulation and Use, Part II

Clinical infectious diseases, 2000-01, Vol.30 (1), p.122-140

2000

Volltextzugriff (PDF)

Resolution of Chlamydia trachomatis Infection Is Associated with a Distinct T Cell Response Profile

Clinical and vaccine immunology, 2015-11, Vol.22 (11), p.1206-1218

2015

Volltextzugriff (PDF)

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children

The Pediatric infectious disease journal, 2000-03, Vol.19 (3), p.187-195

2000

Volltextzugriff (PDF)

Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults

Vaccine, 2007-08, Vol.25 (33), p.6164-6166

2007

Volltextzugriff (PDF)

Pneumococcal Disease: Prospects for a New Generation of Vaccines

Science (American Association for the Advancement of Science), 1994-09, Vol.265 (5177), p.1385-1387

Siber, George R.

1994

Volltextzugriff (PDF)

Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines

The Journal of infectious diseases, 2022-01, Vol.225 (2), p.327-331

2022

Volltextzugriff (PDF)

Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years

Vaccine, 2022-07, Vol.40 (31), p.4190-4198

2022

Volltextzugriff (PDF)

Placental and breast transfer of antibodies after maternal immunization with polysaccharide meningococcal vaccine: a randomized, controlled evaluation

Vaccine, 2002-05, Vol.20 (17), p.2404-2409

2002

Volltextzugriff (PDF)

Corrigendum to “Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years” [Vaccine 40 (2022) 4190–4198]

Vaccine, 2024-06

2024

Volltextzugriff (PDF)

Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial

The Lancet infectious diseases, 2022-07, Vol.22 (7), p.990-1001

2022

Volltextzugriff (PDF)

Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by Heterologous SCB-2019 Vaccine vs a Homologous Booster in CoronaVac-Primed Adults

The Journal of infectious diseases, 2023-11, Vol.228 (9), p.1253-1262

2023

Volltextzugriff (PDF)

Safety, tolerability and immunogenicity of a novel 24-valent pneumococcal vaccine in toddlers: A phase 1 randomized controlled trial

Vaccine, 2024-04, Vol.42 (10), p.2560-2571

2024

Volltextzugriff (PDF)

Stabilization of Tetanus and Diphtheria Toxoids Against Moisture-Induced Aggregation

Proceedings of the National Academy of Sciences - PNAS, 1995-11, Vol.92 (24), p.11234-11238

1995

Volltextzugriff (PDF)

Methodology for a correlate of protection for group B Streptococcus: Report from the Bill & Melinda Gates Foundation workshop held on 10 and 11 February 2021

Vaccine, 2022-07, Vol.40 (32), p.4283-4291

2022

Volltextzugriff (PDF)

Treatment of severe pertussis: a study of the safety and pharmacology of intravenous pertussis immunoglobulin

The Pediatric infectious disease journal, 1999-06, Vol.18 (6), p.505-511

1999

Volltextzugriff (PDF)

Contributions of Native Americans to the global control of infectious diseases

Vaccine, 2007-03, Vol.25 (13), p.2366-2374

2007

Volltextzugriff (PDF)

1 – 25 von 176

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(167)
Mit Volltextzugriff
(125)

Publikationsform

Artikel
(174)
Buchkapitel
(2)

Sprache

Englisch
(176)
Japanisch
(19)

Erscheinungsjahr

n.n

Thema

Science & Technology
(129)
Life Sciences & Biomedicine
(126)
Humans
(105)
Biological And Medical Sciences
(86)
Immunology
(76)
Microbiology
(66)
Infectious Diseases
(62)
Medical Sciences
(50)
Female
(49)
Animals
(48)
Infant
(45)
Fundamental And Applied Biological Sciences. Psychology
(39)
Male
(37)
Immunization
(36)
Adult
(32)
Vaccination
(31)
Antibodies
(29)
Polysaccharides, Bacterial - Immunology
(29)
Child
(28)
Haemophilus Influenzae - Immunology
(28)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

How Can Vaccines Contribute to Solving the Antimicrobial Resistance Problem?

Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies

Which Pneumococcal Serogroups Cause the Most Invasive Disease: Implications for Conjugate Vaccine Formulation and Use, Part I

Serum Serotype-Specific Pneumococcal Anticapsular Immunoglobulin G Concentrations after Immunization with a 9-Valent Conjugate Pneumococcal Vaccine Correlate with Nasopharyngeal Acquisition of Pneumococcus

SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines

Efficacy of a Pneumococcal Conjugate Vaccine against Acute Otitis Media

Identification of novel virus-specific antigens by CD4+ and CD8+ T cells from asymptomatic HSV-2 seropositive and seronegative donors

Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants

The Contribution of Specific Pneumococcal Serogroups to Different Disease Manifestations: Implications for Conjugate Vaccine Formulation and Use, Part II

Resolution of Chlamydia trachomatis Infection Is Associated with a Distinct T Cell Response Profile

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children

Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults

Pneumococcal Disease: Prospects for a New Generation of Vaccines

Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines

Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years

Placental and breast transfer of antibodies after maternal immunization with polysaccharide meningococcal vaccine: a randomized, controlled evaluation

Corrigendum to “Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years” [Vaccine 40 (2022) 4190–4198]

Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial

Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by Heterologous SCB-2019 Vaccine vs a Homologous Booster in CoronaVac-Primed Adults

Safety, tolerability and immunogenicity of a novel 24-valent pneumococcal vaccine in toddlers: A phase 1 randomized controlled trial

Stabilization of Tetanus and Diphtheria Toxoids Against Moisture-Induced Aggregation

Methodology for a correlate of protection for group B Streptococcus: Report from the Bill & Melinda Gates Foundation workshop held on 10 and 11 February 2021

Treatment of severe pertussis: a study of the safety and pharmacology of intravenous pertussis immunoglobulin

Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naïve and exposed individuals in a phase 2/3, double-blind, randomized study

Contributions of Native Americans to the global control of infectious diseases

Suchergebnisse filtern